ABSI vs MXCT: stock comparison and AI forecast
Absci Corp (ABSI) and Maxcyte, Inc. (MXCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABSI Absci Corp
- Market Cap
- $1.75B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MXCT Maxcyte, Inc.
- Market Cap
- $130M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ABSI is 13.4 times larger than MXCT by market capitalization ($1.75B against $130M).
- MXCT turns -114.8% of its revenue into net income, against -2234.6% for ABSI.
- ABSI carries 0.17 times debt per unit of equity, against 0.16 times for MXCT.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABSI | MXCT |
|---|---|---|
| Market Cap | $1.75B | $130M |
| P/B Ratio | 8.78x | 0.82x |
| EPS | $-0.81 | $-0.38 |
| Book Value/Share | $1.16 | $1.54 |
| Revenue/Share | $0.01 | $0.30 |
| FCF/Share | $-0.63 | $-0.23 |
Profitability & Margins
| Metric | ABSI | MXCT |
|---|---|---|
| ROE | -53.0% | -22.4% |
| ROA | – | -19.3% |
| ROIC | – | -23.9% |
| Gross Margin | – | 79.2% |
| Operating Margin | -2676.0% | -134.6% |
| Net Margin | -2234.6% | -114.8% |
| EBT Margin | -2567.4% | -114.8% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | ABSI | MXCT |
|---|---|---|
| Current Ratio | 10.63x | 12.26x |
| Quick Ratio | – | 11.47x |
| D/E Ratio | 0.17x | 0.16x |
| Financial Leverage | – | 1.16x |
| Interest Coverage | -174.4x | -818.0x |
| Working Capital | $189M | $111M |
Cash Flow
| Metric | ABSI | MXCT |
|---|---|---|
| Operating Cash Flow | -$108M | -$23M |
| Free Cash Flow | -$109M | -$24M |
| Capital Spending | -$890K | -$670K |
| FCF/Sales | -6981.0% | -76.1% |
| CapEx/Sales | 57.0% | 2.1% |
Operational Efficiency
| Metric | ABSI | MXCT |
|---|---|---|
| Asset Turnover | – | 0.17x |
| Receivables Turnover | – | 7.9x |
| Inventory Turnover | – | 0.8x |
| Fixed Assets Turnover | 0.1x | 2.1x |
| Days Sales Outstanding | – | 46 days |
| Days Inventory | – | 441 days |
| Payables Period | – | 98 days |
| Cash Conversion Cycle | – | 389 days |
Income Statement
| Metric | ABSI | MXCT |
|---|---|---|
| Total Revenue | $2M | $31M |
| Operating Income | -$126M | -$42M |
| Net Income | -$105M | -$36M |
| R&D Expense | $86M | $17M |
| SG&A Expense | $35M | $47M |
| Cost of Goods Sold | – | $6M |
Dividend & Shareholder Information
| Metric | ABSI | MXCT |
|---|---|---|
| Shares Outstanding | 172M | 103M |
ABSI vs MXCT: stock comparison and AI forecast
Which is bigger, ABSI or MXCT?
ABSI is 13.4 times larger than MXCT by market capitalization ($1.75B against $130M).
Which one does Intratio's AI model rank higher, ABSI or MXCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.